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ABSTRACT
Objectives: Premature ovarian insufficiency (POI) is associated with hypoestrogenism and an increased risk of metabolic 
disorders. In many clinics, a variety of insulin resistance (IR) tests are used during routine clinical assessments. To date, 
there is no clear opinion about which of these tests should be applied in women with premature ovarian insufficiency 
(POI). Therefore, our preliminarily aim was to compare the most frequently used insulin resistance indexes in the clinical 
assessment of a group of POI women and a control group. 
Material and methods: Our retrospective study included 98 women with karyotypically normal spontaneous POI aged 
18–39 years and a control group of 78 healthy women. Each patient was given an oral glucose tolerance test (OGTT) to 
evaluate their insulin release and insulin resistance. In addition, each woman’s insulin resistance (IR) was evaluated us-
ing the homeostasis model assessment for insulin resistance (HOMA-IR), the quantitative insulin sensitivity check index 
(QUICKI), the fasting glucose-to-insulin ratio (FGIR), and Matsuda and McAuley indexes. The two groups’ glucose levels were 
compared at 0, 60 and 120 min of the OGTT. 
Results: At 0 and 60 min of the OGTT, the insulin levels of the POI women were significantly higher than those of the control 
group. The number of women in whom IR was detected using the various kits was comparable between the two groups. 
Conlusions: In conclusion, only the OGTT evaluation revealed a significant difference in insulin concentrations between 
the two study groups. The indexes most commonly used to detect IR did not detect differences in IR between the POI 
women and the members of the healthy control group. QUICKI detected significantly more women with IR within both 
study groups than other tests did.
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INTRODUCTION
Premature ovarian insufficiency (POI) is currently de-
fined as the coexistence of menstrual disorders and typical 
hormonal serum levels. According to the 2015 European So-
ciety of Human Reproduction and Embryology (ESHRE) 
guidelines, a POI diagnosis can be established in patients un-
der 40 years old with oligomenorrhoea/amenorrhoea of at 
least 4–6 months and folliculotropin (FSH) > 25 IU/L [1]. The 
prevalence of POI is ~1% of women < 40 years-old, ~0.1% of 
women < 30 years-old, and ~0.01% of women < 20 years-old 
[2, 3]. POI, previously described in the literature as premature 
ovarian failure (POF), is associated with hypoestrogenism 
and an increased risk of metabolic disorders [4–6]. POI 
can have different aetiologies and is found in women with 
both normal and abnormal karyotypes. Additionally, the 
disease can be associated with different autoimmunological 
conditions, such as Hashimoto’s disease, Addison’s disease, 
and diabetes [7, 8]. 
Taking into account that POI is a hypoestrogenic state 
which can lead to metabolic disorders we wondered if there 
is a difference in any of the commonly used indices that 
would distinguish between POI and healthy subjects.
In many clinics, a variety of insulin resistance (IR) tests 
are used as part of a routine clinical assessment. To date, 
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there is no clear opinion which of these tests should be 
applied in women with POI. Therefore, our preliminary aim 
was to compare the IR indexes commonly used in assessing 
both POI women and members of a healthy control group.
MATERIAL AND METHODS
Study population
Our retrospective study was conducted in the Depart-
ment of Gynecological Endocrinology at the Medical Uni-
versity of Warsaw. Medical records from October 2011 to 
December 2016 were anonymously reviewed. We obtained 
approval for our study from the Ethics Committee of the Medi-
cal University of Warsaw in Poland (AKBE 52/17). Because new 
diagnostic criteria for POI were set in 2015, we also included 
in the study population women who had been previously 
diagnosed with secondary amenorrhoea (i.e., those with 
FSH > 25 and < 40 U/L). Additionally, we included women 
who met the new ESHRE criteria, namely: FSH > 25 IU/L, at 
least 4 months of oligomenorrhoea, and a normal karyotype. 
Our exclusion criteria were as follows: women with a his-
tory of iatrogenic ovarian damage, chemotherapy, pelvic 
surgery, radiotherapy, or metabolic diseases; women pre-
viously diagnosed with polycystic ovary syndrome (PCOS); 
and women who were on hormonal replacement therapy 
or oral contraceptive pills at least 4 weeks prior to entering 
the study.
Control group
Subjects in the control group were recruited from 
healthy women admitted to our outpatient clinic for peri-
odic medical examinations. 
These subjects included women who had a regular 
menstrual cycle (25–35 days) and had not had hormonal 
treatment in the 4 weeks prior to entering the study. All 
the women had a gynaecological examination, laboratory 
tests and transvaginal sonography using a 7.5 MHz vaginal 
probe, Hitachi Aloca UST 9130 sonograph. Their body mass 
index (BMI) was calculated as weight (kg) / height (m2) [9].
Assay
The laboratory parameters included follicle-stimulat-
ing hormone (FSH), luteinizing hormone (LH), oestradiol 
(E2), prolactin (PRL), thyrotropin (TSH), free thyroxine (fT4), 
anti-thyroid peroxidase antibodies (anti-TPO), thyroglobu-
lin-antibodies (anti-TG), total testosterone (T), sex hormone 
binding globulin (SHBG), androstenedione (A), dehydroe-
piandrostenedione sulphate (DHEAS), and 17-hydroxypro-
gesterone (17-OHP).
Our laboratory normal reference ranges during the fol-
licular phase were as follows: FSH, 3.03–8.08 mIU/mL; LH, 
1.8–11.78 mIU/mL; oestradiol, 21–251 pg/mL; prolactin, 
5–35 ng/mL; TSH, 0.35–4.94 µIU/mL; fT4, 9.01–19.05 pmol/L; 
T, 0.1–0.56 ng/mL; SHBG, 19.84–155.2 nmol/L; A, 0.3– 
–3.5 ng/mL; DHEAS, 2.68–9.23 µmol/L; and 17-OHP, 0.3– 
–1.0 ng/mL. Serum anti-TPO levels greater than 34 IU/mL 
and anti-TG > 4.11 were considered positive.
Serum FSH, LH, E2, PRL, TSH, fT4, T, and SHBG were 
measured using an enzyme-linked fluorescent assay (ELFA) 
(VIDAS, BioMerieux). 17-OHP levels were measured using 
an enzyme-linked immunosorbent assay (ELISA) (Euroim-
mun AG Analyzer I). The serum concentration of A was tested 
using the chemiluminescent immunoassay technique (Im-
mulite 2000XP, Siemens Healthineers). Serum insulin and 
cortisol were measured using a chemiluminescent micropar-
ticle immunoassay (CMIA) (Architect i2000SR, Abbott Diag-
nostics). Serum anti-TPO and anti-TG levels were measured 
using an electrochemiluminescence immunoassay (ECLIA) 
(Elecsys and Cobas e analyzers, Roche).
Serum glucose, total cholesterol, triglycerides, high-den-
sity lipoprotein (HDL) cholesterol, and low-density lipopro-
tein (LDL) cholesterol were analysed using an enzymatic 
colorimetric method (Konelab Prime 30i by Thermo Sci-
entific). The free androgen index (FAI) was calculated as T / 
SHBG × 100% [10].
Glucose and insulin concentrations were measured 
at 0, 60, and 120 min after participants were adminis-
tered 75 g of glucose as part of an OGTT. Impaired fasting 
glucose (IFG) was defined as glucose between 100 and 
125 mg/dL. An impaired glucose tolerance test (IGT) was 
defined as a 2 h post-challenge blood glucose level of 140– 
–199 mg/dL. Diabetes was detected when the fasting glucose 
was ≥ 126 mg/dL, random plasma glucose was ≥ 200 mg/dL 
with typical symptoms, or glucose was ≥ 200 mg/dL after 
2 h of a 75 g OGTT [11]. We applied Ten’s study to define 
hyperinsulinaemia (fasting insulin > 15 IU/mL, > 150 IU/mL 
after 1 h of OFTT, or > 75 IU/mL after 2 h of an OGTT) [12]. 
The fasting glucose insulin ratio (FGIR) was obtained by 
dividing the fasting glucose (mg/dL) by the fasting insulin 
(mIU/mL), and the cut-off point of the FGIR for IR was ac-
cepted as 7.2 [13]. 
The quantitative insulin sensitivity check index (QUICKI) 
was calculated using the following formula: 1 / [log fasting 
insulin (mIU/mL) + log fasting glucose (mg/dL)]. IR was 
defined as a QUICKI value < 0.357 [14]. 
The Matsuda index was calculated using the following 
formula: [10.000 / (mean glucose (0–120) × mean insulin 
(0–120) × fasting glucose/fasting insulin]. IR was defined 
as a Matsuda index value < 7.3 [15].
The homeostasis model for insulin resistance (HOMA- 
IR) was calculated as follows: [fasting insulin × fasting glu-
cose/22.5]. Subjects were considered insulin resistant when 
the HOMA-IR score was > 2.5 [16]. 
The McAuley (McA) index was calculated using the fol-
lowing formula: exp [2.63–0.28 ln (insulin in mU/L) — 0.31 ln 
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(triglycerides in mmol/L)]. IR was considered present when 
the McA value was ≥ 5.7 [17].
In the POI group, blood samples were collected on the 
day of admission to the gynaecological department (dur-
ing the amenorrhoea period). In the control group, blood 
samples were collected during the early follicular phase of 
the menstrual cycle (days 3–6). The time elapsed between 
POI diagnosis and OGTT assessment was between 6 and 
36 months.
Statistics
The normality of distributions of continuous variables in 
the examined groups was analysed using the Shapiro-Wilk 
test. Because most of the data had a non-normal distribu-
tion, data was shown as medians, lower and upper quar-
tiles (Q1–Q3), and minimum and maximum values. Because 
the groups possess variations in age, they were compared 
using the regression model adjusted by age for the loga-
rithm of the variables (Tab. 1 and 2). Spearman’s correlation 
coefficient was used to assess the relationship among the 
various insulin indexes, lipid parameters and androgens. 
Additionally, we categorized participants as insulin re-
sistant or not insulin resistant. Categorical variables are 
presented as percentages and numbers of subjects. The 
proportions of IR between the control and POI groups and 
the proportions of IR within groups were compared using 
a test for two proportions (Tab. 3). 
For all analyses, a p-value of < 0.05 for two-sided tests 
was accepted as statistically significant. All calculations were 
performed using IBM SPSS Statistics 24.
RESULTS
A total of 176 women (98 POI and 78 controls) com-
pleted the study. The anthropometric characteristics of the 
POI and control groups are summarized in Table 1.  There 
were no statistically significant differences in serum T, A and 
DHEAS between the POI and control groups. Compared with 
the control group, the POI group had significantly lower 
Table 1. The anthropometric characteristics and hormones in women with POI and in the control group
POI (N=98) Control group (N = 78)
p value
Mean ± SD Range Median (Q1–Q3) Mean ± SD Range
Median
(Q1–Q3)
FSH (mIU/mL) 69.71 ± 25.43 25.17–165 67.7 (49.1–87) 9.05 ± 15.32 3.1–10.91 5.2 (4.3–6) < 0.001
Age 31.48 ± 6.07 18–39 32 (29–36) 27.78 ± 5.25 18–40 27 (24–30) < 0.001
BMI (kg/m²) 23.78 ± 3.563 18–39 23 (21.2–25.9) 22.20 ± 2.94 18–30 22.5 (20.8–24.8) NS
First menses (age) 13.13 ± 1.72 11–18 13 (12–14) 12.56 ± 1.25 10–15 13 (11.7–13) NS
WHR 86.53 ± 12.17 67–122 86.5 (77.7–93.2) 80.28 ± 10.10 65–103 78.5 (73.7–84.5) NS
LH (mIU/mL) 34.52 ± 14.79 9.2–69.4 33.1 (23.3–45) 7.07 ± 8.60 2.0–51.42 4.8 (3.4.3–6.9) < 0.001
E2 (pg/mL) 22.34 ± 31.69 5–252 13.5 (10–21) 51.0 ± 41.23 10–303 41.5 (30–55.2) < 0.001
PRL (ng/mL) 30.0 ± 13.26 6.17–100.6 27.4 (23.1–33.4) 31.51 ± 13.77 6–89.45 30.3 (24.3–36.2) NS
T (ng/mL) 0.40 ± 0.24 0.1–1.8 0.36 (0.2–0.5) 0.37 ± 0.12 0.16–0.74 0.35 (0.3–0.5) NS
SHBG (nmol/L) 53.91 ± 31.85 11.6–148 48.4 (31.4–64.7) 70.39 ± 33.50 7.85–161 63.3 (41.6–92.3) 0.002
A (ng/mL) 2.30 ± 1.11 0.3–5.4 2.1 (1.6–2.9) 2.66 ± 1.02 0.7–4.8 2.7 (1.7–3.5) NS
DHEAS (µmol/L) 5.50 ± 2.77 0.1–13.62 5.3 (3.4–6.4) 6.67 ± 2.05 1.96–12.4 6.5 (5.3–7.9) NS
TSH (mlU/L) 1.56 ± 1.34 0.16–10.3 1.2 (0.9–1.8) 1.58 ± 0.80 0.4–4.4 1.4 (0.9–2) NS
fT4 (pmol/L) 12.65 ± 2.06 6.1–17.1 12.6 (11.2–14.3) 13.32 ± 1.45 9.7–17.08 13.3 (12.2–14.3) NS
anti–TPO (IU/mL) 208.11 ± 557.35 0–2900 5.5 (0.1–32.3) 45.96 ± 210.47 0–1407 0.3 (0.1–0.8) NS
anti–TG (IU/mL) 87.98 ± 240.87 0–1354.2 7.9 (0.8–43.5) 17.70 ± 51.79  0–344.9 1.4 (0.8–7.3) 0.013
OGTTb (mg/dL) 85.29 ± 7.42 67–111 85 (81–89) 84.81 ± 6.32 70–102 85 (81–89) NS
OGTT1hc (mg/dL) 140.89 ± 35.67 56–237 140 (124–159) 136.48 ± 38.64 59–248 138 (110–162)   NS
OGTT2hd (mg/dl) 104.07 ± 29.41 41–189 104 (83–122) 100.49 ± 22.57 56–166 97 (83–114) NS
Ins 0 he (IU/mL) 6.77 ± 3.67 1.8–18 6.0 (4–8.4) 5.58 ± 2.56 1.9–12.3 4.8 (3.5–5.7) 0.032
Ins 1 h (IU/mL) 59.56 ± 51.94 11.4–390 49.2 (31.7–78.7) 41.77 ± 24.275 3.8–120.3 34.9 (23.3–54) 0.017
Ins 2 h (IU/mL) 35.61 ± 30.32 10.2–235 27.3 (17.7–44.4) 36.29 ± 21.48 8.0–118.2 30.8 (19.6–47.9) NS
Cortisolf 12.45 ± 3.64 6.02–20.18 11.8 (9.9–15.2) 12.17 ± 3.70 5.83–18.28 12.2 (8.3–15.5) NS
aFAI — free androgen index; bOGTT — oral glucose tolerance test – fasting serum glucose; cOGTT — 1 hour; dOGTT — 2 hours; einsulin measured before the OGTT; 
fCortisol measured at 8 a.m.; P — value adjusted for age
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values of SHBG [p = 0.002] and 17-OHP [p = 0.007] and high-
er anti-TG levels [p = 0.013].  No significant differences in lipid 
profile were detected between the groups. The OGTT, basal, 
60-min and 120-min glucose levels and 120-min insulin 
levels were comparable between the groups. However, the 
basal and 60 min insulin levels were significantly higher in 
women with POI than in those in the control group (Tab. 1).
There were no significant differences between the POI 
patients and controls for median values of the QUICKI and 
the HOMA, Matsuda, McA, and FGIR indexes (Tab. 2). The 
number of women detected with IR when assessed using 
the various kits was comparable between the two groups 
(Fig. 1).
However, QUICKI proved better than other indexes and 
tests (p < 0.05) at detecting IR in both the POI and control 
group, with larger numbers detected in in the former than in 
the latter (28.57% and 23.07%, respectively) (Tab. 2).
Finally, we determined the correlation of the IR indexes 
we investigated with other hormonal and biochemical pa-
rameters (Tab. 3).
DISCUSSION
POI cases are described as primary when the cause is 
unknown, and as secondary when other conditions are 
involved (e.g., after chemotherapy or surgery). Most POI 
cases are primary [18, 19]. 
As expected, our study recorded lower androgen levels 
in women with POI than in the members of the control 
group, and this is in accordance with previously published 
data [8]. Additionally, higher levels of thyroglobulin antibod-
ies were found in the POI group, which may be due to the 
association between POI and thyroiditis.
It is established that POI is the disease associated with 
hypoestrogenism and characterized by an increased risk of 
cardio-metabolic changes [20–23]. Additionally, hyperinsu-
linaemia is regarded as a surrogate marker of IR [24]. There 
is some data indicating the possible connection between IR 
and the hypo-oestrogenic state [25]. Thus, when considering 
the above relationships between oestrogen deficiency and 
hyperinsulinaemia, we wonder if there may be a difference 
in the indexes of IR between groups. The gold standard 
methods in assessing IR are the euglycaemic insulin clamp 
[26], the intravenous glucose tolerance test (IVGTT), and 
the minimal model approximation of the metabolism of 
glucose (MMAMG) [27]. Unfortunately, these methods are 
rarely applied because of time and cost constraints. In clini-
cal practice, there are many easier methods that can predict 
insulin resistance, and these are used as surrogates for the 
“gold standard” methods.
In our study, the groups did not differ with respect to 
OGTT. However, basal insulin levels and insulin levels after 
1 h of an OGTT were significantly higher in the POI group 
Table 2. The number (percent) of women with insulin resistance in POI and in the control group
POI (N = 98) Control group (N = 78) p value
QUICKI Quicki < 0.357 28.57% (28/98) 23.07% (18/78) NS
Matsuda Matsuda < 7.3 15.3% (15/98) 14.1% (11/78) NS
HOMA-IR Homa > 2.5 16.32% (16/98) 8.97% (7/78) NS
FGIR MG < 7.2 6.12% (6/98) 2.56% (2/78) NS
McA McA ≥ 5.7 5.1% (5/98) 1.28% (1/78) NS
FI FI > 15 4.08% (4/98) 0% (0) NA
HOMA-IR — homeostatic model assessment of insulin resistance; QUICKI — quantitative insulin check index; Matsuda index; FGIR — fasting glucose/insulin ratio; McA, 
McAuley index; FI — fasting insulin > 15; NS — non-significant; NA — not applicable; P-value: POI vs. control group
Table 3. Correlation of insulin resistance indexes with some parameters of POI
Variable
BMI WHR FAI SHBG
r P value r P value r P value r p value
HOMA 0.294 0.007 0.475 0.003 0.207 0.088 –0.379 0.001
QUICKI –0.275 0.013 –0.476 0.003 –0.236 < 0.05 0.357 0.003
FGIR 0.217 < 0.05 –0.396 0.014 NS NS
Matsuda NS –0.461 0.004 –0.288 0.017 0.279 0.020
McA –0.244 0.027 –0.420 0.003 –0.265 0.010 0.392 < 0.001
Fasing Insulin 0.269 0.014 0.500 0.001 NS –0.366 0.002
HOMA-IR — homeostatic model assessment of insulin resistance; QUICKI — quantitative insulin check index; Matsuda index; FGIR — fasting glucose/insulin ratio; McA 
— McAuley index; FI — fasting insulin > 15; NS — non-significant
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than in the control group. Our data are partially in agree-
ment with those presented by Ates et al., where IR measured 
using the HOMA, fasting levels of insulin and glucose appear 
to be normal in women with POI compared with the data 
sets of the control group [5]. Daan et al. measured the basal 
insulin and glucose levels in 83 women with previously 
diagnosed POI. It was found that both parameters were 
lower in the women with POI than in the premenopausal 
controls; however, it is worth noting that the mean age of 
the women with previously diagnosed POI was 49.3 years 
at the time of enrolment in the study [4].
In most studies, the insulin resistant indexes of women 
with polycystic ovary syndrome (PCOS) or diabetes are 
predominantly presented. It is also worth noting that the 
literature presents different levels of fasting insulin or in-
sulin post-glucose load as hyperinsulinaemia and IR. Al-
though there is no consensus on a cut-off point for the 
2 h insulin level to define IR, Stovall et al. reported that 
the mean 2 h post-load insulin levels for non-overweight 
(BMI < 25 kg/m2) and overweight (BMI > 25 kg/m2) patients 
were 34.2 mIU/mL and 70.0 mIU/mL, respectively [28]. Ad-
ditionally, Saxena et al. used a value of the 2 h insulin level 
greater than 41 mIU/mL to determine the presence of IR in 
Indian women with PCOS [29]. 
When we compared the number of women diagnosed 
as IR (considering the QUICKI, HOMA, Matsuda, and FIGR 
indexes) and their medians we found no statistically sig-
nificant differences between the POI and control group. 
However, when we analysed data within the POI group, 
hyperinsulinaemia was more often detected when using 
the QUICKI than when using the other tests. 
Based on our results above, the QUICKI index detected 
many women with hyperinsulinaemia in the POI group; in 
addition, the insulin levels were significantly higher in the POI 
women than in the control group at 0 and 60 min of the OGTT. 
The data from the literature indicates that the frequency 
of detection of IR varies with respect to the index applied. 
For example, according to some data, IR was detected be-
tween 30.4% and 53.6% for the HOMA-IR index and between 
26.8% and 83.9% for the Matsuda index [30, 31]. We did not 
find data regarding the POI population; thus, a comparison 
between POI subjects and healthy controls was not possible. 
We also speculate that the lack of differences in com-
monly use indices between POI women and healthy con-
trols can be the result of a too short time between the 
onset of POI and OGTT assessment. In some studies, an early 
postmenopausal status was not associated with decreased 
insulin sensitivity, as assessed by the hyperinsulinemic-eu-
glycemic clamp [32].
In conclusion, only the OGTT evaluation revealed a sig-
nificant difference in insulin concentrations between the 
two study groups. The indexes most commonly used to 
detect IR did not detect differences in IR between the POI 
women and the members of the healthy control group. 
QUICKI detected significantly more women with IR within 
both study groups than other tests did. We believe that 
studies with a larger sample size should be performed in the 
future to elucidate the meaningfulness of these differences. 






















































POI — premature ovarian insufficiency; 
HOMA-IR — Homeostatic Model assessment 
of insulin resistance; QUICKI — Quantitative 
insulin check index; Matsuda Idex,  
FGIR — fasting glucose/insulin ratio,  
McA — McAuley index; * P-value adjusted 
by age
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